Afatinib Not Recommended Post-CRT for Patients With Squamous Cell Carcinoma of the Head and Neck
Adding afatinib to standard CRT is not recommended for patients with primary unresected, high- or intermediate-risk HNSCC.
All articles by Alexander M. Castellino, PhD
Momelotinib vs Ruxolitinib for Patients With Myelofibrosis
Momelotinib, an oral JAK inhibitor, is non-inferior to ruxolitinib in reducing spleen volume, though not for improving disease-related symptoms, among patients with myelofibrosis.
Eighteen-month ADT Plus RT Recommended Standard for Patients With High-risk Prostate Cancer
Reducing the duration of androgen-deprivation therapy with radiation therapy from 36 months to 18 months is safe for patients with high-risk prostate cancer.
Docetaxel Plus Cyclophosphamide Non-inferior to Anthracycline-based Chemotherapy in Breast Cancer
Patients with early stage, HER2-negative breast cancer may be sufficiently well-treated with docetaxel and cyclophosphamide instead of anthracycline-based chemotherapy.
aBSI Is of Prognostic Significance in Castration-resistant Prostate Cancer
An automated bone scan index at baseline is clinically validated as a prognostic biomarker in men with castration-resistant prostate with bone metastases.
Bevacizumab Improves PFS, But Not OS, When Combined With Chemotherapy in SCCHN
Bevacizumab added to a standard platinum doublet chemotherapy regimen did not improve OS, though PFS was improved, among patients with cancer of the head and neck.
Intermittent Letrozole May Benefit Some Patients With Breast Cancer
Study data suggest that some women with breast cancer may benefit from intermittent over continuous letrozole treatment.
FLOT Is Superior to ECF/ECX Among Patients With Gastric Cancer
Perioperative FLOT significantly improved PFS and OS among patients with resectable gastric cancers compared with standard ECF/ECX.
Pembrolizumab Active in Advanced Gastric Cancer
Pembrolizumab monotherapy showed clinical efficacy in patients with advanced gastric cancer.
High Activity for Nivolumab Alone and With Ipilimumab in Small-cell Lung Cancer
Nivolumab alone or combined with ipilimumab provided durable responses in patients with advanced small-cell lung cancer whose disease progressed on prior platinum therapies.
- Loading...
Loading...
Next post in ASCO 2017
Loading... 
Loading...